Earning after market close:
All position are closed:
TRP Trade:
TRP Short at 56.69 Close at 56.03
Shorted $AOL at $44.16
AOL Short: in at $43.01, and out at $42.60
90% of the stock s that pops drop, take short and then long
RPRX Long @ 9.78 closed at 10.05
VHC Long @ 4.48 and closed at $4.88
VHC Long: @4.72 closed at 4.84
RPRX Support
RPRX Long @9.17, and out 9.45
RPRX Long @9.96 and out at 10.15
GDOT Long: 18.69 and closed at 19.24
RAD Long @ 5.80 out at 5.84
RAD Long:
Day Trade watchlist:
ORCL (Implied earning move of 5%), RHT (implied earning move of 11%), TIBX (implied earning move of 8%)
TRP Trade:
TRP Trade |
TRP Short at 56.69 Close at 56.03
Shorted $AOL at $44.16
AOL Short: in at $43.01, and out at $42.60
90% of the stock s that pops drop, take short and then long
AOL |
RPRX Long @ 9.78 closed at 10.05
RPRX |
VHC Long @ 4.48 and closed at $4.88
VHC Long: @4.72 closed at 4.84
RPRX Support
RPRX |
RPRX Long @9.17, and out 9.45
RPRX Long @9.96 and out at 10.15
GDOT Long: 18.69 and closed at 19.24
GDOT |
RAD Long:
Day Trade watchlist:
MCHX, LIVE, VVUS, AUXL, AVNR, RPRX, GDOT, RAD, ZGNX, FANG, VNET, MNDL
Only IPO today is PRQR
News
that matter:
ConAgra
beats by $0.04, reports revs in-line; reaffirms FY15 EPS guidance; sees Q2 EPS
comparable to last year (CAG)
Salix
Pharma announces Cipla has granted Salix exclusive rights under certain patent
applications in the 'Rifaximin Complexes' patent family controlled by Cipla (SLXP)
USEC Inc. expects to complete the
final steps necessary to emerge from its Chapter 11 restructuring on September
30, 2014, under the name Centrus Energy Corp.; co's new common stock shares are
expected to begin trading on the New York Stock Exchange under the ticker
symbol 'LEU' on that date. (USU)
Rite Aid
beats by $0.07, reports revs in-line; lowers FY15 EPS, rev guidance, narrows
comp guidance (RAD)
Auxilium
Pharma presents XIAFLEX (:CCH) data from MULTICORD and retreatment studies at
the ASSH Annual Meeting; data support CCH could be used to treat two affected
joints concurrently; positive results presented from additional studies
evaluating CCH retreatment for recurrent contracture (AUXL)
IHS beats by $0.05, reports revs
in-line; narrows FY14 EPS guidance; raises FY14 revenue guidance (IHS)
No comments:
Post a Comment